PMID- 19073721
OWN - NLM
STAT- MEDLINE
DCOM- 20090216
LR  - 20211020
IS  - 1098-5514 (Electronic)
IS  - 0022-538X (Print)
IS  - 0022-538X (Linking)
VI  - 83
IP  - 5
DP  - 2009 Mar
TI  - Reevaluating the CD8 T-cell response to herpes simplex virus type 1: involvement 
      of CD8 T cells reactive to subdominant epitopes.
PG  - 2237-45
LID - 10.1128/JVI.01699-08 [doi]
AB  - In C57BL/6 (B6) mice, most herpes simplex virus (HSV)-specific CD8 T cells 
      recognize a strongly immunodominant epitope on glycoprotein B (gB498) and can 
      inhibit HSV type 1 (HSV-1) reactivation from latency in trigeminal ganglia (TG). 
      However, half of the CD8 T cells retained in latently infected TG of B6 mice are 
      not gB498 specific and have been largely ignored. The following observations from 
      our current study indicate that these gB498-nonspecific CD8 T cells are HSV 
      specific and may contribute to the control of HSV-1 latency. First, following 
      corneal infection, OVA257-specific OT-1 CD8 T cells do not infiltrate the 
      infected TG unless mice are simultaneously immunized with OVA257 peptide, and 
      then they are not retained. Second, 30% of CD8 T cells in acutely infected TG 
      that produce gamma interferon in response to HSV-1 stimulation directly ex vivo 
      are gB498 nonspecific, and these cells maintain an activation phenotype during 
      viral latency. Finally, gB498-nonspecific CD8 T cells are expanded in ex vivo 
      cultures of latently infected TG and inhibit HSV-1 reactivation from latency in 
      the absence of gB498-specific CD8 T cells. We conclude that many of the CD8 T 
      cells that infiltrate and are retained in infected TG are HSV specific and 
      potentially contribute to maintenance of HSV-1 latency. Identification of the 
      viral proteins recognized by these cells will contribute to a better 
      understanding of the dynamics of HSV-1 latency.
FAU - Sheridan, Brian S
AU  - Sheridan BS
AD  - Graduate Program in Immunology, University of Pittsburgh School of Medicine, 
      Pittsburgh, Pennsylvania, USA.
FAU - Cherpes, Thomas L
AU  - Cherpes TL
FAU - Urban, Julie
AU  - Urban J
FAU - Kalinski, Pawel
AU  - Kalinski P
FAU - Hendricks, Robert L
AU  - Hendricks RL
LA  - eng
GR  - T32 AI060525/AI/NIAID NIH HHS/United States
GR  - T32-AI060525/AI/NIAID NIH HHS/United States
GR  - R01 EY005945/EY/NEI NIH HHS/United States
GR  - R01-EY05945/EY/NEI NIH HHS/United States
GR  - P30-EY08098/EY/NEI NIH HHS/United States
GR  - P30 EY008098/EY/NEI NIH HHS/United States
GR  - K23 AI064396/AI/NIAID NIH HHS/United States
GR  - K23-AI064396/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20081210
PL  - United States
TA  - J Virol
JT  - Journal of virology
JID - 0113724
RN  - 0 (Antigens, Viral)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (Viral Envelope Proteins)
RN  - 0 (glycoprotein B, Simplexvirus)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Antigens, Viral/immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cells, Cultured
MH  - Epitopes, T-Lymphocyte/*immunology
MH  - Female
MH  - Herpes Simplex/*immunology/virology
MH  - Herpesvirus 1, Human/*immunology/physiology
MH  - Interferon-gamma/immunology
MH  - Lymphocyte Activation
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Trigeminal Ganglion/immunology/virology
MH  - Viral Envelope Proteins/immunology
MH  - Virus Latency
PMC - PMC2643732
EDAT- 2008/12/17 09:00
MHDA- 2009/02/17 09:00
PMCR- 2009/09/01
CRDT- 2008/12/17 09:00
PHST- 2008/12/17 09:00 [entrez]
PHST- 2008/12/17 09:00 [pubmed]
PHST- 2009/02/17 09:00 [medline]
PHST- 2009/09/01 00:00 [pmc-release]
AID - JVI.01699-08 [pii]
AID - 1699-08 [pii]
AID - 10.1128/JVI.01699-08 [doi]
PST - ppublish
SO  - J Virol. 2009 Mar;83(5):2237-45. doi: 10.1128/JVI.01699-08. Epub 2008 Dec 10.